CYduct Diagnostics Inc (CYDX)

[mgrego]

I agree. FDA is often afraid of the Type I error (releasing a drug or medical device that harms ppl) which then leads to Type 2 bias (being over cautious) and you are right, the legal environment adds unnecessary costs to the healthcare system.

In speaking of only Obamacare and its impact of SNDY, estimates of 30 million Americans will now have access to healthcare. 30M new patients. Say half are women, and 80% of that total would undergo routine breast cancer screening. I see a larger market. To some degree, it may force adoption of technologies that bring diagnostic efficacy and cost savings to the table to maintain some cost control. I see it reducing the resistance to wide spread adoption of microendoscopy as opposed hindering it.

GLTA